Table 1 |
||||
|
Baseline characteristics of the patients who reached the primary end-point (day 28) |
||||
| Quinine |
Atovaquone/Proguanil |
Artemether/Lumefantrine |
||
|
|
||||
| n |
30 |
30 |
30 |
|
|
|
||||
| sex |
m/f |
16/14 |
16/14 |
18/12 |
|
|
||||
| age |
range |
6 – 50 |
6 – 35 |
8 – 40 |
| mean |
19.2 |
19.9 |
18.1 |
|
| median |
16 |
18 |
17 |
|
|
|
||||
| Temperature (C°) |
range |
36.0 – 39.5 |
36.0 – 39.3 |
35.6 – 39.9 |
| mean |
37.4 |
37.3 |
37.5 |
|
| median |
37.2 |
37.3 |
37.4 |
|
|
|
||||
| Parasitaemia |
range |
360 – 63,000 |
400 – 69,880 |
480 – 83,600 |
| mean |
15,469 |
13,028 |
21,189 |
|
| median |
6,740 |
4,960 |
9,300 |
|
|
|
||||
| Symptoms |
Headache |
30 |
30 |
30 |
| Nausea/vomiting |
21 |
17 |
22 |
|
| Shivering |
23 |
26 |
21 |
|
| Diarrhea |
4 |
2 |
3 |
|
|
|
||||
| Actual daily dose (mg/kg) |
range |
30.5 – 36 |
15 – 23 |
2.3 – 4.6 |
| mean |
34.9 |
19.5 |
3.4 |
|
| stdev |
1.6 |
1.9 |
0.6 |
|
|
|
||||
|
Baseline patients' characteristics of the patients who reached the primary end-point (day 28) were not significantly different between the three treatment groups in respect to age (Kruskal-Wallis-test, p = 0,504), sex (χ2-test, p = 0,835), parasitaemia (Kruskal-Wallis-test, p = 0,444), body temperature (Kruskal-Wallis-test, p = 0,860). There is also no significant difference in these baseline characteristics of the treatment groups when comparing all 97 treated patients. |
||||
|
Gürkov et al. Malaria Journal 2008 7:179 doi:10.1186/1475-2875-7-179 |
||||
